The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Comparative Effectiveness of Therapies for Graves' Hyperthyroidism: A Systematic Review and Network Meta-Analysis
Open accessAbstract
CONTEXT: Several treatment options are available for Graves' disease (GD), including antithyroid drugs (ATDs), radioactive iodine (RAI), and thyroidectomy. OBJECTIVE: The primary outcome was to determine the relapse rates of various treatment options. The secondary outcome was to present data regarding adverse effects of ATDs. DATA SOURCES: We searched multiple databases through March 2012. STUDY SELECTION: Eligible studies were randomized clinical trials and comparative cohort studies in adults that included 2 or more treatment options for GD. DATA EXTRACTION: Two reviewers independently selected studies, appraised study quality, extracted outcome data, and determined adverse effect profiles. DATA SYNTHESIS: We found 8 studies with 1402 patients from 5 continents. Mean follow-up duration in months was: ATDs, 57; RAI, 64; and surgery, 59. Studies were at moderate to high risk of bias. Network meta-analysis suggested higher relapse rates with ATDs (52.7%; 352 of 667) than RAI (15%, 46 of 304) (odds ratio = 6.25; 95% confidence interval, 2.40-16.67) and with ATDs than surgery (10%; 39 of 387) (odds ratio = 9.09; 95% confidence interval, 4.65-19.23). There was no significant difference in relapse between RAI and surgery. Examination of 31 cohort studies identified adverse effects of ATDs in 692 of 5136 (13%) patients. These were more common with methimazole, mainly owing to dermatological complications, whereas hepatic effects were more common with propylthiouracil use. CONCLUSION: We confirm the relatively high relapse rate of ATD therapy in comparison with RAI or surgery, along with a significant side effect profile for these drugs. These data can inform discussion between physicians and patients regarding the choice of therapy for GD. The limited quality of the evidence in the literature underlines the need for future randomized clinical trials in this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a recent systematic review of eight studies that included 667 GD patients receiving MMI or PTU, 13% of patients experienced adverse events (122).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [122]
In the citing paper
“Hepatocellular injury occurred in 2.7% of patients taking PTU and 0.4% of patients taking MMI.”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [122]
In the citing paper
“The minor allergic reactions included pruritus or a limited, minor rash in 6% of patients taking MMI and 3% of patients taking PTU (122).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
(2014) · Medical Entomology and Zoology · Cited by 17,633
Thyroid hormone and the cardiovascular system.
Klein, I., & Ojamaa, K. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440707 · Cited by 2,300
Empirical assessment of effect of publication bias on meta-analyses
Sutton, A. J. (2000) · BMJ · doi:10.1136/bmj.320.7249.1574 · Cited by 1,398
Network meta‐analysis for indirect treatment comparisons
Lumley, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1201 · Cited by 1,206
Cited by
Sorted by citations
Items 101–200 of 249
Engelbrecht-Wiggans, E. A., Carlisle, K. M., Yunasan, E., Fan, C., Munir, K. M., Terhune, J. H., Turner, D., & Hu, Y. (2024) · Surgery · doi:10.1016/j.surg.2024.05.050 · Cited by 6
Liu, J., Fu, J. H., Duan, Y., & Wang, G. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00258 · Cited by 6
Pregnancy after definitive treatment for G raves’ disease – Does treatment choice influence outcome?
Elston, M. S., Tu'akoi, K., Meyer-Rochow, G. Y., Tamatea, J. A. U., & Conaglen, J. V. (2014) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12196 · Cited by 6
Kurozumi, A., Okada, Y., Arao, T., Narisawa, M., Torimoto, K., Yamamoto, S., & Tanaka, Y. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0152 · Cited by 6
Methimazole discontinuation before radioiodine therapy in patients with Graves’ disease
Zakavi, S. R., Khazaei, G., Sadeghi, R., Ayati, N., Davachi, B., Bonakdaran, S., Nooghabi, M. J., & Mousavi, Z. (2015) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000384 · Cited by 6
Shifting Trends and Informed Decision-Making in the Management of Graves' Disease
Seib, C. D., Chen, J., & Iagaru, A. H. (2020) · Thyroid · doi:10.1089/thy.2020.0114 · Cited by 6
Santhanam, P., Sólnes, L. B., Nath, T., Roussin, J.-P., Gray, D. S., Frey, E. C., Sgouros, G., & Ladenson, P. W. (2021) · Scientific Reports · doi:10.1038/s41598-021-97408-y · Cited by 6
Wang, X., Liu, W., Rui, Z., Zheng, W., Tan, J., Li, N., & Yu, Y. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0087 · Cited by 6
Is Hyperthyroidism Diagnosed and Treated Appropriately in the United States?
Asban, A. A., Dream, S. Y., & Lindeman, B. M. (2019) · Advances in Surgery · doi:10.1016/j.yasu.2019.04.007 · Cited by 6
Antigen-specific therapy of Graves acute disease and orbitopathy by induction of tolerance
Ungerer, M. (2018) · Frontiers in bioscience · doi:10.2741/4688 · Cited by 5
Carbimazole-Induced Jaundice in Thyrotoxicosis: A Case Report
Maliyakkal, A. M., Elhadd, T. A., Naushad, V. A., Shaath, N. M., Farfar, K. L., Ahmed, M. S., & Basheer, S. M. (2021) · Cureus · doi:10.7759/cureus.15241 · Cited by 5
A rare case of carbimazole-induced hepatitis in a patient with Graves’ disease
Burgin, S., Zanetto, U., Cooney, R. M., & Basu, A. (2015) · JRSM Open · doi:10.1177/2054270415602827 · Cited by 5
Methodological Quality Assessment of Meta-Analyses of Hyperthyroidism Treatment
Qin, Y., Yao, L., Shao, F., Yang, K., & Tian, L. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-119545 · Cited by 5
Medical treatment of thyrotoxicosis
Scappaticcio, L., Bellastella, G., Maiorino, M. I., Giovanella, L., & Esposito, K. (2021) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.21.03334-3 · Cited by 5
Hidalgo, J., Vallejo, S., Kawkgi, O. M. E., Ospina, N. S., Maraka, S., & Brito, J. P. (2022) · Endocrine · doi:10.1007/s12020-022-02989-x · Cited by 5
Self-citationBolakale‐Rufai, I. K., Abioro, I., Ngene, S. O., & Woldeamanuel, Y. W. (2023) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2022.0225.r1.19102022 · Cited by 5
Xiang, P., Li, Q., Cui, G., Xu, N., Xiao, Q., Qu, X., Zhang, Y., Chen, Y., Wei, X., Wang, Q., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117753 · Cited by 5
Владимировна, П. А., & Verbovoy, A. F. (2017) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2017-95-9-780-788 · Cited by 5
Antithyroid drugs and the dose–risk balance: a meta-analysis on agranulocytosis in hyperthyroidism
Stieben, L. A. R., Brun, L. R., Doddi, P. N., & Brance, M. L. (2025) · Endocrine · doi:10.1007/s12020-025-04372-y · Cited by 4
Iratherapie dans la maladie de Basedow: place et efficacité
Sellem, A., Elajmi, W., Mhamed, R. B., Oueslati, N., Ouertani, H., & Hammami, H. (2020) · Pan African Medical Journal · doi:10.11604/pamj.2020.36.341.21623 · Cited by 4
Radioactive Iodine Treatment in Hyperthyroidism and Cancer Mortality—A Still Controversial Issue
Biondi, B. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.26361 · Cited by 4
Wang, X., Li, T., Li, Y., Wang, Q., Cai, Y., Wang, Z., Shi, Y., Yang, T., & Zheng, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05129-3 · Cited by 4
Self-citationA Weighted Genetic Risk Score Using Known Susceptibility Variants to Predict Graves Disease Risk
Ma, Y., Zhao, S., Li, L., Sun, F., Ye, X., Yuan, F., Jiang, D., Zhou, Z., Zhang, Q.-Y., Wan, Y., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01551 · Cited by 4
Wang, M., & Yu, Y. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0555 · Cited by 4
Ibrahim, S., Rawashdeh, A. A., Barakat, M., Al-Bsoul, A., & Alqudah, R. (2022) · Pharmacy Practice · doi:10.18549/pharmpract.2022.1.2586 · Cited by 4
Long-term outcome of treatments for Graves disease in the children and adolescent population
Jawwad, M., Ahmed, S. A., Zaidi, S. M. M., Fatmi, S. A. A., Ashraf, M. H., Naeem, S., & Chola, M. S. (2023) · Endocrine · doi:10.1007/s12020-023-03371-1 · Cited by 4
So erkennen und behandeln Sie die Hyperthyreose
Schmidt, M. C. (2017) · CME · doi:10.1007/s11298-017-5982-5 · Cited by 4
Surgery for Hyperthyroidism Lowers Cardiovascular Mortality Compared with Radioactive Iodine
Day, A. J., Yeh, M. W., & Livhits, M. J. (2018) · Clinical Thyroidology · doi:10.1089/ct.2018;30.15-17 · Cited by 4
Sekulić, V., Rajic, M., Mž, V., Ilić, S., Stević, M., & Kojić, M. (2015) · PubMed · doi:10.1967/s002449910300 · Cited by 4
Vergauwen, L., Stinckens, E., Villeneuve, D. L., & Knapen, D. (2022) · OECD series on adverse outcome pathways · doi:10.1787/447c5cba-en · Cited by 5
Kim, K. J., Song, E., Kim, M., Kwon, H., Ku, E. J., Kwon, H. W., Yoon, J. H., Lee, E. K., Lee, W. W., Park, Y. J., et al. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2464 · Cited by 3
Gatta, E., Pirola, I., Gotti, A., Fredi, M., Bellini, P., Dondi, F., Morandi, R., Casella, C., Bertagna, F., Franceschini, F., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf144 · Cited by 4
Mohammadi, B., Raziabadi, S. M., & Vessally, E. (2022) · Silicon · doi:10.1007/s12633-022-02197-2 · Cited by 3
Kanokwongnuwat, W., Penpong, N., & Sangsri, C. (2022) · Thyroid Research · doi:10.1186/s13044-022-00142-4 · Cited by 3
Cardinez, N., BAKHSH, A. M. K., & Perkins, B. A. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.01.002 · Cited by 3
Salman, M. A., Assal, M. M., Salman, A., & Elsherbiney, M. (2023) · Indian Journal of Surgery · doi:10.1007/s12262-023-03692-5 · Cited by 6
Shimmaru, K., Inami, M., Hamaoka, A., Fujiwara, N., Morioka, T., Emoto, M., & Kamei, N. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej23-0062 · Cited by 3
Gökbulut, P. (2023) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2023.195 · Cited by 3
Jansen, H. I., van Beek, C. H., Bisschop, P. H. L. T., Heijboer, A. C., Bruinstroop, E., & Boelen, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02358-7 · Cited by 4
Long-term follow-up of treatment outcomes in Graves’ disease and toxic nodular disease
Veríssimo, D., Pereira, B., Vinhais, J., Ivo, C., Martins, A. C., Silva, J. N. E., Passos, D., Lopes, L., de Castro, J. J., & Marcelino, M. (2024) · Endocrine · doi:10.1007/s12020-024-04000-1 · Cited by 3
Yu, F., Ma, W., Li, X., Zhang, R., Kang, F., Yang, W., Wang, R., & Wang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1391014 · Cited by 3
Guo, Y., Huang, D., Sun, J., Zhai, Z., Xiao, H.-W., Hao, W., Wang, Q., Huang, J., Jin, M., & Lu, W. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s484910 · Cited by 3
The evolution and hotspots of radioactive iodine therapy in hyperthyroidism: a bibliometric analysis
Chen, S., Gou, R.-Q., & Zhang, Q. (2024) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001940 · Cited by 3
Kim, J. A., Kim, K. J., Choi, J., Kim, K. J., Song, E., Yu, J. H., Kim, N. H., Yoo, H. J., Seo, J. A., Kim, N. H., et al. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2093 · Cited by 3
Thyroidectomy in Patients with Graves’ Disease
Opoku‐Boateng, A., Wang, T. S., & Sosa, J. A. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_8 · Cited by 3
Accuracy of123I-Sodium Thyroid Imaging in Calculating Thyroid Volume
Fecca, C., Moon, J., Posocco, D. F., Zhao, H., & Dadparvar, S. (2022) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.121.263395 · Cited by 3
Methimazole Desensitization in a Patient Experiencing a Thionamide-induced Hypersensitivity Reaction
Arguinchona, J., Mahajan, A., Gonzalez‐Estrada, A., & Filippis, E. D. (2024) · JCEM Case Reports · doi:10.1210/jcemcr/luae066 · Cited by 2
Chen, Y., Ren, Z., Zhou, X., & Gao, P. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s540261 · Cited by 3
Graves’ Disease: What Is the Role and Timing of Surgery?
Elfenbein, D. M., & Sippel, R. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-20523-6_8 · Cited by 2
Lanas, A., DÍAZ, P. V., Eugenin, D., González, F., Cid, P., Cordero, F., Araya, V., Liberman, C., Marcela Barberán, M., Gac, P., et al. (2017) · Revista médica de Chile · doi:10.4067/s0034-98872017000400003 · Cited by 2
Teelucksingh, S., Motilal, S., Bailey, H. H., Sookhai, S. P., Sooknanan, J., Soongoon-Padarath, S. Y. A. N., Sookram, A., Sookram, V., Spann, J. K. I., Stewart, D. J. U., et al. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0544 · Cited by 2
Listewnik, M. H., Piwowarska-Bilska, H., Jasiakiewicz, K., & Birkenfeld, B. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/137779 · Cited by 2
Observational Study on Outcomes after Radioiodine Ablation in Hyperthyroid Patients
Pamnani, H., Jindal, R., Khare, J., Sharma, M., Siddiqui, A., & Wangnoo, S. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_29_22 · Cited by 2
Happel, C., Bockisch, B., Leonhäuser, B., Sabet, A., Grünwald, F., & Groener, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-47228-z · Cited by 2
Atypical Clinical Courses of Graves' Disease Confound Differential Diagnosis of Hyperthyroidism
Yamaguchi, Y., Okajima, F., Sugihara, H., Iwabu, M., & Emoto, N. (2023) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2024_91-104 · Cited by 2
Correlation Between TRAb and Early Onset Hypothyroidism After 131I Treatment for Gravesʼ Disease
Song, Q., Fang, Z., Wang, S., Liu, Z., Xiao, W., Zong, H., & Xie, Y. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2272-5165 · Cited by 2
Yuan, Y., Li, X., Ni, W., Huang, W., Chen, G., Xu, S., & Liu, C. (2024) · Endocrine · doi:10.1007/s12020-024-04048-z · Cited by 2
Kim, J. H., Shin, J., Kim, M. S., & Moon, J. H. (2025) · JMIR mhealth and uhealth · doi:10.2196/56738 · Cited by 2
Kim, J. Y., Lee, K., Choi, E., Oh, J. S., Lee, E. B., Chae, H. W., Ko, T., & Song, K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf542 · Cited by 2
A Clinical Debate: What Is the Therapeutic Choice for Recurrent Graves’ Hyperthyroidism?
Abdi, H., Zakavi, S. R., & Azizi, F. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.108876 · Cited by 2
Chachamovitz, D. S. D. O., Vigário, P. D. S., Carvalho, R. C., Silvestre, D. H., Moerbeck, A. E. V., Soffientini, M. G., Luna, É. L. G., Rosemberg, C. W., Mainenti, M. R. M., Vaisman, M., et al. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000079 · Cited by 2
Chen, Y., Xie, S. P., He, F., & Chen, J. (2017) · PubMed Central · doi:10.22038/aojnmb.2016.7401 · Cited by 2
Sim, S. Y., Lethem, C., & Coppini, D. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.46 · Cited by 2
Mengistu, H. S., Getahun, K. T., Alemayehu, L., & Gezahagn, S. (2022) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s350984 · Cited by 4
Wu, Y., Chang, Y., Tsai, C.-J., Chan, Y., Chi, S., Chou, F., Lin, W., & Yang, Y. T. (2023) · Scientific Reports · doi:10.1038/s41598-023-29885-2 · Cited by 2
Leitha, T., Schartel, M., Hurtl, I., Bednar, R., König, F., Mayrhofer, K., & Pietschmann, F. (2020) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001315 · Cited by 2
Kim, M. J., Kim, Y. A., Cho, S. W., Kim, S., Lee, K. E., Park, Y. J., Park, D. J., & Cho, B. Y. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081629 · Cited by 2
Özçelik, S., Çelik, M., Vural, A., Aydın, B., & Gözü, H. I. (2021) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2021.05.517 · Cited by 1
Patient outcomes following thyroid surgery for thyrotoxicosis
Selwyn, D. M., How-Hong, E., Tan, H., & England, R. J. (2022) · The Journal of Laryngology & Otology · doi:10.1017/s0022215122000664 · Cited by 1
Treating Hyperthyroidism With Radioiodine
Park, J., & Colletti, P. M. (2026) · Clinical nuclear medicine open. · doi:10.1097/nm9.0000000000000084 · Cited by 1
Gatta, E., Morandi, R., Casella, C., Negro, R., Rotondi, M., & Cappelli, C. (2026) · Endocrine · doi:10.1007/s12020-026-04740-2 · Cited by 1
Endocrinologic management of hyperthyroidism and the impact on thyroid eye disease
Rajaii, F., Gupta, S., & Douglas, R. S. (2014) · Taiwan Journal of Ophthalmology · doi:10.1016/j.tjo.2014.03.001 · Cited by 1
Treatment for Graves’ Disease and its Recurrence
Hussain, D. S. Z. (2017) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v5i7.100 · Cited by 1
Maurer, E., & Holzer, K. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-63317-5_9 · Cited by 1
Wu, D., Liu, B., Xian, W., Yang, Y., Li, J., Hong, S., Li, Y., & Xiao, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267814 · Cited by 1
Crespo-Morfin, P. B., Guerrero-Gutiérrez, M. A., Damus-Ligonio, S. I., Guízar-Enríquez, K. O., Phinder-Puente, M. E., & Pérez‐Nieto, O. R. (2024) · Medicina Crítica · doi:10.35366/116322 · Cited by 2
Thyroid peroxidase antibodies and their role in predicting outcomes in Graves’ disease treatment
Gewert, K., Topi, G., Planck, T., & Calissendorff, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1517283 · Cited by 2
Kim, K. J., Song, E., Kim, M., Kwon, H., Ku, E. J., Kwon, H. W., Yoon, J. H., Lee, E. K., Lee, W. W., Park, Y. J., et al. (2025) · International Journal of Thyroidology · doi:10.11106/ijt.2025.18.1.65 · Cited by 1
Treatment of relapsed hyperthyroidism
Chung, J. H. (2018) · Journal of Korean Medical Association · doi:10.5124/jkma.2018.61.4.248 · Cited by 1
Djiba, B., Demba, D., Sow, D., Assane, N. M., Mané, D. I., Limane, B. A., Mariama, K.-C., Anna, S., & Maimouna, N.-M. (2020) · Open Journal of Internal Medicine · doi:10.4236/ojim.2020.102017 · Cited by 1
Treatment of Grave’s Disease in Adults
Álvarez, M., & Duarte, L. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97563 · Cited by 1
Thyroidectomy for Graves’ disease
Almquist, M., Triponez, F., & Seib, C. D. (2021) · doi:10.58974/bjss/azbc001 · Cited by 1
Management of Hyperthyroidism in the Setting of Thyroid Eye Disease
Rajaii, F., Gupta, S., & Douglas, R. S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1746-4_4
Evidence-Based Discussion of Treatment Options for Graves’ Disease
Brito, J. P., & Montori, V. M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_5
Self-citationUtilidad de la plasmaféresis en el tratamiento preoperatorio de la tirotoxicosis
Valladares, S., Ciudin, A., González, Ó., & Lecube, A. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.04.008
Antithyroid Drug Treatment Remains the First Choice in Uncomplicated Graves’ Disease
Burger, A. (2014) · Clinical Thyroidology · doi:10.1089/ct.2014;26.73-74
Usefulness of preoperative plasmapheresis in patients with thyrotoxicosis
Valladares, S., Ciudin, A., González, Ó., & Lecube, A. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.10.003
Bartalena, L. (2018) · Endocrinology · doi:10.1007/978-3-319-45013-1_17
Primary treatment of Graves’ disease: Comparison of radioiodine and antithyroid drugs.
Wallace, I. R. (2015) · Medical Research Archives · doi:10.18103/mra.v2i5.410
Koçer, B. (2018) · Springer eBooks · doi:10.1007/978-3-319-78476-2_7
Agranulocytosis: A Rare Complication and Management Paradox
Khare, J. (2018) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000124
Тарасенко, С. О., Дубров, С. О., Товкай, О. А., Lishhynskyi, P. O., Миколайович, К. Д., & Кунатовський, М. В. (2018) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.14.6.2018.146064
Prognostic factors analysis for a calculated dose of 131I therapy in Graves' disease in China
Zhao, W., Lv, Q., Fei, Y., Zhao, Z., & Zhang, Y.-W. (2019) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.17.03708-1
Failure of RAI Therapy in Graves' Disease Is Related to Higher Initial Serum FT 4 and TRAb Levels
Samuels, M. H. (2019) · Clinical Thyroidology · doi:10.1089/ct.2019;31.46-48
Cytopathology in the Thyroid of Graves Disease
Hang, J. (2019) · Springer eBooks · doi:10.1007/978-981-13-1897-9_54
Comparative Safety of Therapies for Hyperthyroidism Planning Pregnancy: A Network Meta-analysisPreprint
Fang, X., Huang, H., Lin, W., Liang, J., Wen, J., & Chen, G. (2020) · medRxiv · doi:10.1101/2020.05.11.20097774
Pathogenesis and Medical Management of Thyroid Eye Disease
Carniciu, A. L., & Kahana, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-41720-8_57
Singh, K. R., & Mishra, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96958
Overt Hyperthyroidism and Subclinical Hyperthyroidism: Who and How to Treat
Cozzi, R. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-80267-7_4
Pharmacological Survey of Graves' Disease: A Mini Review
Saifi, A., Taheri, N. S., Mansourian, H. R., & Mansourian, A. R. (2021) · Journal of Clinical and Basic Research · doi:10.52547/jcbr.5.2.42
Metadata
- Authors
- Sundaresh, V., Brito, J. P., Wang, Z., Prokop, L. J., Stan, M. N., Murad, M. H., & Bahn, R. S.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Bahn, Rebecca S.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-09
- Volume
- 98
- Issue
- 9
- Pages
- 3671-3677
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3763977
- OpenAlex
- W1983002130
- Cited by
- 250
- References
- 31
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 22 · 2023: 28 · 2022: 22 · 2021: 28 · 2020: 18 · 2019: 21 · 2018: 20 · 2017: 16 · 2016: 14 · 2015: 18 · 2014: 14 · 2013: 1
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- National Institutes of Health (UL1TR000135, TR000135)
- National Center for Advancing Translational Sciences (CTSA Grant UL1 TR000135, TR000135)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Keywords
- Graves' disease, Graves' hyperthyroidism, antithyroid drugs, radioactive iodine, thyroidectomy, relapse rate, adverse drug reactions, methimazole, propylthiouracil, comparative effectiveness
- MeSH terms
- Female, Graves Disease, Humans, Iodine Radioisotopes, Male, Recurrence, Antithyroid Agents, Thyroidectomy, Databases, Factual, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
